tebu-bio signs agreement with HemaCare for Europe

tebu-bio (Le Perray en Yvelines, France) recently announced their agreement with HemaCare (Van Nuys, CA USA) to provide their range of biological blood products throughout Europe.

252 logoHemaCare is a leader in cell and tissue collection, processing and cell therapy, providing high-quality biological material derived from normal and mobilized peripheral blood, bone marrow and cord blood.

Jean-François Têtu (Sales Manager – Cells & Cell Based Assays at tebu-bio) says “By signing this agreement with HemaCare, tebu-bio is pleased to again enlarge our range of sourcing possibilities. I am proud to say that, more than ever, our commitment to source the very cell type that fits the researcher’s needs is true.”

With HemaCare as the latest addition to their offer, tebu-bio now offers European researchers access to highly pure and characterized primary human cells and blood components collected from IRB consented normal donors and patients.  The samples are available through an extensive registry but also collected  on demand, with donors matching researchers’ specifications. tebu-bio’s well-established logistics ressources make shipment of cryopreserved and fresh samples all over Europe possible, literally from donors to researchers.

For more information on HemaCare’s products now available in Europe, contact Jean-François Têtu or visit tebu-bio.com.

Sara Pierre
Written by Sara Pierre
Sara Pierre is the Communication Manager at tebu-bio, and also happy to help the authors post their content on this blog.